Tarrytown, NY, Jan 31, 2008 – PsychoGenics Inc. today announced that it has entered into an additional drug discovery agreement with Eli Lilly and Company (NYSE:LLY). Per the agreement, Lilly will supply pre-candidate compounds that PsychoGenics will evaluate using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders.